MASON, Ohio / Apr 19, 2023 / Business Wire / AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an investor education webcast in conjunction with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. The company also announced that it will be participating in the upcoming 2023 Bank of America Health Care Conference.
AtriCure’s management will be participating in the 2023 Bank of America Health Care Conference. Management is scheduled to present on May 10, 2023 at 11:00 a.m. Eastern Time.
AtriCure and Canaccord Genuity will be hosting the Cryo Nerve Block Therapy Investor Education Webcast at 12:30 pm Eastern Time on Tuesday, May 16, 2023. The webcast will include a moderated question and answer session with management and a key opinion leader.
Interested parties may access a live and archived webcast of each presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
| Last Trade: | US$28.57 |
| Daily Change: | -0.04 -0.14 |
| Daily Volume: | 415,991 |
| Market Cap: | US$1.390B |
October 15, 2024 October 01, 2024 August 27, 2024 August 22, 2024 July 30, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
